Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

Kennedy R Lees; Erich Bluhmki; Rüdiger von Kummer; Thomas G Brott; Danilo Toni; James C Grotta; Gregory W Albers; Markku Kaste; John R Marler; Scott A Hamilton; Barbara C Tilley; Stephen M Davis; Geoffrey A Donnan; Werner Hacke; Kathryn Allen; Jochen Mau; Dieter Meier; Gregory del Zoppo; Adriana Araujo de Souza e Silva; K S Butcher; M W Parsons; P A Barber; C Levi; C Bladin; G Byrnes; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group

doi:10.1016/S0140-6736(10)60491-6

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

Kennedy R Lees, Erich Bluhmki, Rüdiger von Kummer, Thomas G Brott, Danilo Toni, James C Grotta, Gregory W Albers, Markku Kaste, John R Marler, Scott A Hamilton, Barbara C Tilley, Stephen M Davis, Geoffrey A Donnan, Werner Hacke, Kathryn Allen, Jochen Mau, Dieter Meier, Gregory del Zoppo, Adriana Araujo de Souza e Silva, K S ButcherM W Parsons, P A Barber, C Levi, C Bladin, G Byrnes, ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group

Neurologisk Afd. N

1811 Citationer (Scopus)

Abstract

Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	375
Udgave nummer	9727
Sider (fra-til)	1695-703
Antal sider	9
DOI	https://doi.org/10.1016/S0140-6736(10)60491-6
Status	Udgivet - 15 maj 2010

Adgang til dokumentet

10.1016/S0140-6736(10)60491-6

Citationsformater

Lees, K. R., Bluhmki, E., von Kummer, R., Brott, T. G., Toni, D., Grotta, J. C., Albers, G. W., Kaste, M., Marler, J. R., Hamilton, S. A., Tilley, B. C., Davis, S. M., Donnan, G. A., Hacke, W., Allen, K., Mau, J., Meier, D., del Zoppo, G., de Souza e Silva, A. A., ... ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group (2010). Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 375(9727), 1695-703. https://doi.org/10.1016/S0140-6736(10)60491-6

Lees, KR, Bluhmki, E, von Kummer, R, Brott, TG, Toni, D, Grotta, JC, Albers, GW, Kaste, M, Marler, JR, Hamilton, SA, Tilley, BC, Davis, SM, Donnan, GA, Hacke, W, Allen, K, Mau, J, Meier, D, del Zoppo, G, de Souza e Silva, AA, Butcher, KS, Parsons, MW, Barber, PA, Levi, C, Bladin, C, Byrnes, G & ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group 2010, 'Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials', Lancet, bind 375, nr. 9727, s. 1695-703. https://doi.org/10.1016/S0140-6736(10)60491-6

@article{60e0bccbf7e74a4b93dbe7e6db119181,

title = "Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials",

abstract = "Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.",

author = "Lees, {Kennedy R} and Erich Bluhmki and {von Kummer}, R{\"u}diger and Brott, {Thomas G} and Danilo Toni and Grotta, {James C} and Albers, {Gregory W} and Markku Kaste and Marler, {John R} and Hamilton, {Scott A} and Tilley, {Barbara C} and Davis, {Stephen M} and Donnan, {Geoffrey A} and Werner Hacke and Kathryn Allen and Jochen Mau and Dieter Meier and {del Zoppo}, Gregory and {de Souza e Silva}, {Adriana Araujo} and Butcher, {K S} and Parsons, {M W} and Barber, {P A} and C Levi and C Bladin and G Byrnes and {ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group} and Derk Krieger",

year = "2010",

month = may,

day = "15",

doi = "10.1016/S0140-6736(10)60491-6",

language = "English",

volume = "375",

pages = "1695--703",

journal = "Lancet",

issn = "1474-547X",

publisher = "The/Lancet Publishing Group",

number = "9727",

}

TY - JOUR

T1 - Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

AU - Lees, Kennedy R

AU - Bluhmki, Erich

AU - von Kummer, Rüdiger

AU - Brott, Thomas G

AU - Toni, Danilo

AU - Grotta, James C

AU - Albers, Gregory W

AU - Kaste, Markku

AU - Marler, John R

AU - Hamilton, Scott A

AU - Tilley, Barbara C

AU - Davis, Stephen M

AU - Donnan, Geoffrey A

AU - Hacke, Werner

AU - Allen, Kathryn

AU - Mau, Jochen

AU - Meier, Dieter

AU - del Zoppo, Gregory

AU - de Souza e Silva, Adriana Araujo

AU - Butcher, K S

AU - Parsons, M W

AU - Barber, P A

AU - Levi, C

AU - Bladin, C

AU - Byrnes, G

AU - ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group

AU - Krieger, Derk

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.

AB - Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis.

U2 - 10.1016/S0140-6736(10)60491-6

DO - 10.1016/S0140-6736(10)60491-6

M3 - Journal article

C2 - 20472172

SN - 1474-547X

VL - 375

SP - 1695

EP - 1703

JO - Lancet

JF - Lancet

IS - 9727

ER -

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater